Your browser is no longer supported. Please, upgrade your browser.
Settings
NTRP Neurotrope, Inc. daily Stock Chart
NTRP [NASD]
Neurotrope, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own18.97% Shs Outstand13.49M Perf Week1.82%
Market Cap9.07M Forward P/E- EPS next Y-1.11 Insider Trans- Shs Float10.17M Perf Month-18.05%
Income-15.60M PEG- EPS next Q-0.29 Inst Own17.60% Short Float2.32% Perf Quarter-87.80%
Sales- P/S- EPS this Y16.30% Inst Trans1.19% Short Ratio0.44 Perf Half Y-87.37%
Book/sh1.64 P/B0.41 EPS next Y12.00% ROA-71.70% Target Price1.00 Perf Year-89.42%
Cash/sh1.58 P/C0.43 EPS next 5Y- ROE-77.60% 52W Range0.63 - 8.40 Perf YTD-81.18%
Dividend- P/FCF- EPS past 5Y35.90% ROI- 52W High-92.00% Beta2.12
Dividend %- Quick Ratio25.90 Sales past 5Y- Gross Margin- 52W Low6.67% ATR0.09
Employees5 Current Ratio25.90 Sales Q/Q- Oper. Margin- RSI (14)15.15 Volatility6.66% 12.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.40% Profit Margin- Rel Volume0.51 Prev Close0.66
ShortableYes LT Debt/Eq0.00 EarningsNov 07 Payout- Avg Volume536.60K Price0.67
Recom3.00 SMA20-10.35% SMA50-77.30% SMA200-86.43% Volume272,057 Change2.24%
Sep-11-19Downgrade Janney Buy → Neutral $1
Jun-18-19Initiated Janney Buy $14
May-16-18Initiated Maxim Group Buy $16
Oct-08-19 08:30AM  Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value PR Newswire
Oct-04-19 10:09AM  Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock? Zacks
Oct-01-19 09:14AM  Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System Zacks -7.16%
Sep-30-19 09:58AM  Medtronic's All Business Lines Grow Despite Cost Concerns Zacks +6.58%
08:59AM  Boston Scientific (BSX) Upbeat on Results of EVOLVE Study Zacks
Sep-27-19 08:45AM  NuVasive Announces Innovations in Robotics Spine Surgery Line Zacks
Sep-26-19 11:24AM  Align Gains on Innovation Despite Poor Case Shipment in China Zacks
09:47AM  Natera (NTRA) Scales 52-Week High: What's Driving the Stock? Zacks
Sep-24-19 11:25AM  FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR Zacks -5.73%
09:20AM  Insulet Receives FDA Approval for ACE Pump Implementation Zacks
Sep-23-19 09:44AM  Bruker (BRKR) Enters Into Alliance With Murdoch University Zacks
Sep-20-19 11:44AM  Will Neurotrope (NASDAQ:NTRP) Spend Its Cash Wisely? Simply Wall St. -8.07%
09:12AM  Neogen Forms Partnership With IGS to Enhance Beef Profile Zacks
Sep-19-19 08:41AM  Medtronic Receives European Nod for Glucose Monitoring System Zacks
Sep-18-19 09:22AM  Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line Zacks +10.37%
07:57AM  Abbott Receives European Nod for Pediatric Heart Devices Zacks
Sep-16-19 08:29AM  Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement Zacks
08:26AM  Medtronic (MDT) Earns Dow Jones Sustainability Recognition Zacks
Sep-13-19 10:54AM  Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes Zacks
09:07AM  CryoLife Enters Agreement With Endospan for Aortic Stent Zacks
Sep-11-19 09:04AM  Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring Zacks
Sep-10-19 08:00AM  Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care Zacks -8.00%
Sep-09-19 03:05PM  Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment MarketWatch -77.27%
02:42PM  Failure of Alzheimers Disease Study Creates a New Penny Stock Bloomberg
09:20AM  Neurotrope shares crash after Alzheimer's drug fails in trial Reuters
09:11AM  LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod Zacks
08:30AM  Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease PR Newswire
Sep-05-19 08:19AM  Neurotrope Sees Hammer Chart Pattern: Time to Buy? Zacks -7.92%
Aug-21-19 10:41AM  Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock? Zacks +5.58%
Aug-13-19 08:30AM  Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy PR Newswire -11.52%
Aug-05-19 08:30AM  Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results PR Newswire
Jul-17-19 08:30AM  Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team PR Newswire
Jul-15-19 08:30AM  Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease PR Newswire
Jul-11-19 08:30AM  Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented PR Newswire -7.18%
Jun-24-19 08:30AM  Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019 PR Newswire
Jun-03-19 08:30AM  Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019 PR Newswire
May-30-19 08:30AM  Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019 PR Newswire
May-27-19 08:11AM  Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87% Simply Wall St.
Apr-19-19 05:15PM  Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel PR Newswire
Apr-01-19 08:30AM  Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer PR Newswire
Mar-21-19 09:55AM  Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease PR Newswire +9.81%
Mar-13-19 08:30AM  Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease PR Newswire
Mar-11-19 08:30AM  Neurotrope Reports Year End 2018 Financial Results PR Newswire
Feb-08-19 08:30AM  Neurotrope to Participate in the BIO CEO & Investor Conference PR Newswire
Feb-04-19 08:30AM  Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute PR Newswire
Jan-03-19 08:30AM  Neurotrope to Participate in the Sachs Associates 2nd Annual Neuroscience Innovation Forum PR Newswire
Dec-24-18 10:46AM  Biotech company offering Alzheimers disease patients hope with new drug Yahoo Finance Video
Dec-17-18 09:02AM  Neurotrope Announces the Appointment of Two New Board Members PR Newswire
09:01AM  Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease PR Newswire
09:00AM  Neurotrope Announces $22.5 Million Registered Direct Offering PR Newswire
Nov-19-18 09:00AM  Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-24-18 08:30AM  Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD PR Newswire
Sep-27-18 08:30AM  Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Sep-26-18 08:30AM  Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018) PR Newswire
Sep-05-18 08:30AM  Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome PR Newswire
Aug-30-18 06:45AM  Neurotrope Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-28-18 08:30AM  Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018 PR Newswire
Aug-13-18 08:30AM  Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results PR Newswire
Jul-25-18 08:30AM  At AAIC 2018, Neurotrope Presents Additional Clinical Results Showing Cognitive Improvement in Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients PR Newswire
Jul-17-18 02:17PM  Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed? Benzinga
Jul-16-18 08:30AM  Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease PR Newswire
Jul-11-18 08:30AM  Neurotrope Appoints Leading Experts in Alzheimer's Disease to its Scientific Advisory Board (SAB) PR Newswire
Jul-02-18 08:30AM  Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting PR Newswire
May-07-18 08:30AM  Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients PR Newswire
Mar-09-18 10:21AM  Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says Benzinga
Feb-28-18 08:30AM  Neurotrope to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire -8.74%
Feb-07-18 08:30AM  Neurotrope to Present at BIO CEO & Investor Conference PR Newswire
Jan-25-18 08:30AM  Neurotrope to Present at NobleCon 14th Annual Institutional Investor Conference PR Newswire
Jan-05-18 09:28AM  Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data PR Newswire
Dec-19-17 08:30AM  Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease PR Newswire -6.50%
Dec-18-17 08:30AM  Neurotrope Appoints Charles S. Ryan as Chief Executive Officer PR Newswire
Aug-09-17 08:30AM  Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results PR Newswire
Jul-19-17 11:16AM  Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 PR Newswire
Jul-17-17 11:36AM  NTRP INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of a Complaint Filed to Recover Losses Suffered by Investors in Neurotrope, Inc. and a Lead Plaintiff Deadline of July 17, 2017 Accesswire
10:02AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Neurotrope, Inc. (NTRP) & Lead Plaintiff Deadline: July 17, 2017 Accesswire
Jul-14-17 11:58PM  MONDAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
07:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Neurotrope, Inc. of Class Action Lawsuit and Upcoming Deadline - NTRP Accesswire
05:30PM  Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Neurotrope, Inc. (NTRP) and Encourages Investors with Losses to Contact the Firm Before July 17, 2017 Business Wire
03:06PM  Rosen Law Firm Reminds Neurotrope, Inc. Investors of Important July 17 Deadline in Class Action - NTRP PR Newswire
May-03-17 02:58PM  A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It? TheStreet.com
May-01-17 04:17PM  Tech Leads Nasdaq to a New Record; Congressional Funding Bill Boosts S&P 500 TheStreet.com
12:03PM  Why Is Neurotrope (NTRP) Stock Crashing Today? Zacks
10:33AM  Neurotrope Alzheimer's drug data fails to impress; shares crater Reuters
07:18AM  Neurotrope Spins a Failed Alzheimer's Drug Study TheStreet.com
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.